LLY

Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program.

IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs federal budget issues

International and domestic tax issues. Implementation of PL 119-21. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. Issues related to pharmaceutical manufacturing and development. Drug importation, prescription drug safety, value and access.

Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs.

Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD). Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026. Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026. Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).

Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.

Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.